Point72 Asset Management and affiliates reported beneficial ownership of 2,710,817 shares of Avalo Therapeutics common stock, representing 5.2% of the class as of the close of business on May 22, 2026. The filing states Point72 Asset Management and Point72 Capital Advisors have shared voting and dispositive power over these shares through holdings of Point72 Associates, and that Steven A. Cohen controls the reporting entities. The statement is filed as a joint Schedule 13G under Rule 13d-1(k) and is accompanied by a Joint Filing Agreement (Exhibit 99.1).
Positive
None.
Negative
None.
Insights
Point72 reports a passive, >5% stake in Avalo Therapeutics as of May 22, 2026.
Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen jointly report beneficial ownership of 2,710,817 shares (5.2%) with shared voting and dispositive power via Point72 Associates. The filing is presented on a Schedule 13G, indicating a passive reporting posture under Rule 13d-1(k).
Key dependencies include the composition of the underlying fund holdings and any future amendments should the position become active. Subsequent filings would clarify changes in voting stance or percentage ownership.
Key Figures
Shares beneficially owned:2,710,817 sharesPercent of class:5.2%Filing date / time anchor:05/22/2026+3 more
6 metrics
Shares beneficially owned2,710,817 sharesBeneficial ownership as of May 22, 2026
Percent of class5.2%Percent of Avalo Therapeutics common stock as of May 22, 2026
Filing date / time anchor05/22/2026Ownership figures are as of the close of business on this date
CUSIP05338F306Avalo Therapeutics common stock CUSIP listed on cover page
Sole voting power0.00 sharesReported sole voting power for each reporting person
Shared voting/dispositive power2,710,817 sharesShared voting and dispositive power reported for each reporting person
Key Terms
Schedule 13G, Rule 13d-1(k), beneficially owned, dispositive power
4 terms
Schedule 13Gregulatory
"This statement is filed by: Point72 Asset Management ... as a joint Schedule 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Rule 13d-1(k)regulatory
"agreed to file this jointly in accordance with the provisions of Rule 13d-1(k)"
beneficially ownedfinancial
"Amount beneficially owned: The information required by Item 4(a) is set forth"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
dispositive powerfinancial
"Shared Dispositive Power 2,710,817.00"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
What stake does Point72 report in Avalo Therapeutics (AVTX)?
Point72 reports beneficial ownership of 2,710,817 shares, equal to 5.2% of Avalo Therapeutics common stock as of May 22, 2026. The position is reported jointly by Point72 entities and Steven A. Cohen.
Does the Schedule 13G filing indicate active control by Point72?
No. The filing is a Schedule 13G filed under Rule 13d-1(k), which typically indicates a passive investment posture rather than an active acquisition or control intent.
Who holds voting and dispositive power over the reported shares?
The filing states shared voting and shared dispositive power of 2,710,817 shares are held via Point72 Associates, managed by Point72 Asset Management and affiliated with Point72 Capital Advisors.
Is Steven A. Cohen personally owning the shares reported?
The filing indicates Mr. Cohen controls Point72 Asset Management and Point72 Capital Advisors but states he and the corporate filers directly own no shares; the holdings are reported as beneficial via Point72 Associates.
What exhibits accompany the Schedule 13G filing?
The filing includes a Joint Filing Agreement as Exhibit 99.1 among Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen, authorizing the joint Schedule 13G submission.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Avalo Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
05338F306
(CUSIP Number)
05/22/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
05338F306
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,710,817.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,710,817.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,710,817.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
05338F306
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,710,817.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,710,817.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,710,817.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
05338F306
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,710,817.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,710,817.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,710,817.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Avalo Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
1500 Liberty Ridge Drive, Suite 321, Wayne, PA 19087
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Avalo Therapeutics, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the shares of Common Stock held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Each of Cubist Systematic Strategies, LLC, Point72 Asia (Singapore) Pte. Ltd. and Point72 (DIFC) Limited are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the shares of Common Stock reported herein.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the "Act").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
05338F306
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on May 22, 2026.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.
(b)
Percent of class:
5.2 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on May 22, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on May 22, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on May 22, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on May 22, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding shares of Common Stock.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
